Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories

This article was originally published in The Pink Sheet Daily

Executive Summary

Hikma must divest rights to three drugs under Roxane Labs deal as Federal Trade Commission aims to preserve as many as five competitors in some markets.

Advertisement

Related Content

Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register